Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells $25,366.04 in Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Richard A. Graham sold 2,482 shares of the stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $10.22, for a total value of $25,366.04. Following the transaction, the senior vice president now owns 346,839 shares of the company’s stock, valued at $3,544,694.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Theravance Biopharma Stock Up 0.6 %

Shares of TBPH stock opened at $10.29 on Friday. Theravance Biopharma, Inc. has a 52-week low of $8.25 and a 52-week high of $12.03. The firm’s 50-day moving average is $9.37 and its 200-day moving average is $10.00.

Institutional Investors Weigh In On Theravance Biopharma

Large investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD boosted its position in Theravance Biopharma by 2.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 37,916 shares of the biopharmaceutical company’s stock worth $412,000 after purchasing an additional 948 shares during the period. UBS Group AG raised its holdings in Theravance Biopharma by 45.0% in the 1st quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 1,101 shares during the period. Yakira Capital Management Inc. lifted its position in Theravance Biopharma by 3.6% during the first quarter. Yakira Capital Management Inc. now owns 32,656 shares of the biopharmaceutical company’s stock worth $354,000 after acquiring an additional 1,128 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Theravance Biopharma by 2.6% during the second quarter. Legal & General Group Plc now owns 58,904 shares of the biopharmaceutical company’s stock worth $534,000 after acquiring an additional 1,516 shares during the period. Finally, Royal Bank of Canada grew its position in shares of Theravance Biopharma by 33.8% in the second quarter. Royal Bank of Canada now owns 6,532 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 1,649 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Analysts Set New Price Targets

TBPH has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, August 8th. StockNews.com assumed coverage on shares of Theravance Biopharma in a research note on Thursday, October 5th. They set a “hold” rating for the company.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.